(3-piperidine)carbothioamide | 172261-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3-piperidine)carbothioamide
• 英文别名: Piperidine-3-carbothioamide
• CAS: 172261-29-9
• 化学式: C₆H₁₂N₂S
• 分子量: 144.241
• InChiKey: RKQQPWMQPZQNDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-氰基哌啶 以 氨基甲醇 、 水 为溶剂， 生成 (3-piperidine)carbothioamide
  参考文献：
  名称：

  5-HT.sub.3 receptor agonist, novel thiazole derivative and intermediate

  摘要：

  提供一种含有噻唑衍生物作为有效成分的5-HT.sub.3受体，其化学式为(I)：##STR1## 其中A环被取代或未取代，并表示一个苯环或一个带有一个或两个杂原子的杂环；L.sub.1或L.sub.2中的一个表示单键，另一个不存在或表示一个烷基或烯基基团；R表示：##STR2##

  公开号：

  US05834499A1

文献信息

• HETEROARYL-SUBSTITUTED PIPERIDINES
  申请人：Heimbach Dirk

  公开号：US20090306139A1

  公开（公告）日：2009-12-10

  The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumour diseases.

  这项发明涉及新颖的杂环取代哌啶，涉及它们的制备过程，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。
• [EN] COMPOSITIONS OF FATOSTATIN BASED HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSITIONS DE COMPOSÉS HÉTÉROCYCLIQUES À BASE DE FATOSTATINE ET UTILISATIONS ASSOCIÉES
  申请人：FGH BIOTECH

  公开号：WO2016105491A1

  公开（公告）日：2016-06-30

  The present invention relates to compounds, pharmaceutical compositions and formulations that have a structure (I). The compounds comprise a heterocyclic ring where W, X, Y, and Z generally and independently are S, N or C with the proviso that at least 2 of these positions in the ring are other than carbon. A pyridine or a substituted pyridine A ring and a phenyl or a substituted phenyl B ring are covalently bonded to the heterocyclic ring. Further provided are methods for treating a metabolic disorder, cell proliferative disease, reducing body weight or increasing thermogenesis during weight loss with the compounds of structure as described or pharmaceutically acceptable salt or stereoisomer thereof or both.

  本发明涉及具有结构（I）的化合物、制药组合物和配方。这些化合物包括一个杂环环，其中W、X、Y和Z通常且独立地是S、N或C，但至少有2个这些位置在环中是非碳的。一个吡啶或取代的吡啶A环和一个苯或取代的苯B环与杂环环共价键合。此外，还提供了使用所述结构的化合物或其药学上可接受的盐或立体异构体或两者治疗代谢性疾病、细胞增殖性疾病、减轻体重或增加减重期间的热效应的方法。
• 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0749966A1

  公开（公告）日：1996-12-27

  A 5-HT3 receptor agonist containing a thiazole derivative represented by general formula (I) as the effective ingredient; a specified compound useful as a 5-HT3 receptor agonist; and a specified thioamide derivative useful as an intermediate therefor. wherein each symbol represents the following meaning: Ring A: the following ring which may be substituted by one or more substituents selected from the group consisting of a halogen atom, a lower alkyl group and a lower alkoxyl group: 1) a benzene ring, or 2) a 5-membered or 6-membered unsaturated heterocyclic ring having one or two hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, L1 and L2: one of them represents a single bond, and the other one represents non-existence, or an alkylene group having 1 to 4 carbon atoms or an alkenylene group having 2 to 5 carbon atoms, R: a group represented by one of the following formulae: L3: a lower alkylene group, L4: a single bond or a lower alkylene group, R1 and R2: the same or different and individually a hydrogen atom, a lower alkyl group or an amino-protecting group, R3: a hydrogen atom, a lower alkyl group, an oxo group or a protected or unprotected amino group, R4: non-existence or a hydrogen atom, a lower alkyl group, an aralkyl group or an amino-protecting group, Ring B: the following monocyclic or bicyclic ring which may contain an oxygen atom: 1) a nitrogen-containing saturated heterocyclic ring having 4 to 16 ring-forming atoms, or 2) a nitrogen-containing heterocyclic ring having one unsaturated bond and 4 to 16 ring-forming atoms, and Ring D: a saturated carbon ring having 4 to 8 ring-forming atoms,

  一种 5-HT3 受体激动剂，含有作为有效成分的通式(I)代表的噻唑衍生物；一种用作 5-HT3 受体激动剂的特定化合物；以及一种用作其中间体的特定硫酰胺衍生物。 其中各符号代表以下含义： 环 A：可被选自卤素原子、低级烷基和低级烷氧基的一个或多个取代基取代的下环： 1) 苯环，或 2) 5 元或 6 元不饱和杂环，其中有一个或两个杂原子，选自由氮原子、氧原子和硫原子组成的组、 L1 和 L2：其中一个代表单键，另一个代表不存在的键，或代表具有 1 至 4 个碳原子的亚烷基或具有 2 至 5 个碳原子的烯基、 R：由下式之一代表的基团： L3：低级亚烷基、 L4：单键或低级亚烷基、 R1和R2：相同或不同，各自为氢原子、低级烷基或氨基保护基团、 R3：一个氢原子、一个低级烷基、一个氧代基团或一个受保护或不受保护的氨基、 R4：不存在或为氢原子、低级烷基、芳烷基或氨基保护基团、 环 B：可含有一个氧原子的单环或双环： 1) 具有 4 至 16 个成环原子的含氮饱和杂环，或 2) 具有一个不饱和键和 4 至 16 个成环原子的含氮杂环，以及 环 D：具有 4 至 8 个成环原子的饱和碳环、
• Compositions of fatostatin based heterocyclic compounds and uses thereof
  申请人：FGH BIOTECH, INC.

  公开号：US10328064B2

  公开（公告）日：2019-06-25

  The present invention relates to compounds, pharmaceutical compositions and formulations that have a structure (I). The compounds comprise a heterocyclic ring where W, X, Y, and Z generally and independently are S, N or C with the proviso that at least 2 of these positions in the ring are other than carbon. A pyridine or a substituted pyridine A ring and a phenyl or a substituted phenyl B ring are covalently bonded to the heterocyclic ring. Further provided are methods for treating a metabolic disorder, cell proliferative disease, reducing body weight or increasing thermogenesis during weight loss with the compounds of structure as described or pharmaceutically acceptable salt or stereoisomer thereof or both.

  本发明涉及具有结构（I）的化合物、药物组合物和制剂。这些化合物包括一个杂环，其中 W、X、Y 和 Z 一般独立地为 S、N 或 C，但环中至少有 2 个位置是碳以外的位置。吡啶或取代吡啶 A 环和苯基或取代苯基 B 环以共价键连接到杂环上。进一步提供了用所述结构的化合物或其药学上可接受的盐或立体异构体或两者治疗代谢紊乱、细胞增殖性疾病、减轻体重或在减肥过程中增加产热的方法。
• COMPOSITIONS OF FATOSTATIN BASED HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：FGH Biotech

  公开号：EP3237413A1

  公开（公告）日：2017-11-01